At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 15 enrolled
Drug / intervention
Sildenafil citrate +1 moredrug
Likely dose
Sildenafil citrate 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Renin- Angiotensin and Fibrinolysis Interaction in Humans: Effect of Long-term PDE-5 Inhibition on Glucose Homeostasis. Sub-study
In Brief
A Phase 4 clinical trial evaluating Sildenafil citrate and Placebo Oral Capsule for Metabolic Syndrome. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Our research proposal will determine if PDE-5 inhibition exerts a favorable effect on insulin signaling pathways in skeletal muscle of subjects with impaired fasting glucose and/or impaired glucose tolerance.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedMay 2014
Primary CompletionOct 2016
Study CompletionDec 2016
TodayJul 2026
First PostedMay 2, 2014
Enrollment StartApr 1, 2014
Primary CompletionOct 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.2 years ago
Interventions
Sildenafil citratedrug
Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
Placebo Oral Capsuledrug
placebo capsules, 1 capsule po three times a day for 3 months